Taxanes in head and neck cancer

Future Oncology

Volumn 1, Issue 6, 2005, Pages 829-839

  Schrijvers, Dirk ^a   Vermorken, Jan B ^b  

^a Ziekenhuisnetwerk Antwerpen Campus Middelheim ^*  (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

docetaxel; head and neck cancer; paclitaxel

Indexed keywords

TAXOID;

HEAD AND NECK TUMOR; HUMAN; REVIEW;

HEAD AND NECK NEOPLASMS; HUMANS; TAXOIDS;

EID: 33745690838     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.829     Document Type: Review

References (71)

1. Vokes E, Weichselbaum R, Lippmann S, Hong W: Head and neck cancer. N. Engl. J. Med. 328, 184-194 (1993).
2. Decker J, Goldstein J: Current concepts in otolaryngology. Risk factors in head and neck cancer. N. Engl. J. Med. 306, 1151-1155 (1982).
3. Gleich LL, Salamone FN: Molecular genetics of head and neck cancer. Cancer Control 9, 369-378 (2002).
4. Neville BW, Day TA: Oral Cancer and Precancerous Lesions. CA Cancer J. Clin. 52,195-215 (2002).
5. Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA: The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol. Head Neck Surg. 130, 1269-1275 (2004).
6. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl. 2), 3-8 (2004).
7. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab. Dispos. 30, 438-445 (2002).
8. Schrijvers D, Vermorken JB: Role of taxoids in head and neck cancer. Oncologist 5, 199-208 (2000).
9. Schrijvers D, Vermorken JB: Taxanes in the treatment of head and neck cancer. Curr. Opin. Oncol. 17, 218-224 (2005).
10. Gibson MK, Li Y, Murphy B, Hussain MH et al.:: Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Co-operative Oncology Group. J. Clin. Oncol. 23, 3562-3567 (2005).
11. Smith R, Thornton D, Allen J: A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative studies. Semin. Oncol. 22, 41-46 (1995).
12. Gebbia V, Testa A, Cannata G et al.: Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur. J. Cancer 32, 901-902 (1996).
13. Forastiere A, Shank D, Neuberg D et al.: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82, 2270-2274 (1998).
14. Damascelli B, Patelli GL, Lanocita R et al.: A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am. J. Roentgenol. 181, 253-60 (2003).
15. Catimel G, Verweij J, Mattijssen V et al.: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 5, 533-537 (1994).
16. Dreyfuss A, Clark J, Norris C et al.: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 14, 1672-1678 (1996).
17. Couteau C, Chouaki N, Leyvraz S et al.: A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 81, 457-62 (1999).
18. Inuyama Y, Kataura A, Togawa K et al.: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho 26, 107-16 (1999).
19. Frasci G, Comella P, Parziale A et al.: Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Ann. Oncol. 8, 291-293 (1997).
20. Licitra L, Capri G, Fulfaro F et al.: Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. Ann. Oncol. 8, 1157-1158 (1997).
21. Schilling T, Heinrich B, Kau R et al.: Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 54, 89-95 (1997).
22. Hitt R, Hornedo J, Colomer R et al.: Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Semin. Oncol. 24(Suppl. 2), 58-64 (1997).
23. Thodtmann F, Theiss F, Kemmerich M et al.: Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol. 9, 335-337 (1998).
24. Adamo V, Maisano R, Laudani A et al.: Phase II study paclitaxel and cisplatin in advanced and recurrent head and neck cancer. Eur. J. Cancer 35(suppl 4), 178 (1999).
25. Pfreundner L, Hoppe F, Willner J et al.: Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas-a possibility for organ preservation. Radiother. Oncol. 68, 163-170 (2003).
26. Adamo V, Ferraro G, Pergolizzi S et al.: Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 40, 525-531 (2004).
27. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 23, 3562-3567 (2005).
28. Dunphy FR, Boyd JH, Kim HJ et al.: A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer 79, 2016-2023 (1997).
29. Fountzilas G, Skarlos D, Athanassiades A et al.: Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 8, 451-455 (1997).
30. Stathopoulos G, Rigatos S, Papakostas P et al.: Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur. J. Cancer 33, 1780-1783 (1997).
31. Junor E, Paul J, Robertson A et al.: Phase I dose finding study of paclitaxel in combination with carboplatin in advanced and recurrent squamous carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 18, 407a (1999).
32. Pivot X, Cals L, Cupissol D, Guardiola E et al.: Phase II trial of a paclitaxelcarboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology 60, 66-71 (2001).
33. Clark JI, Kancharla K, Qamar R et al.: Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Lung Cancer 34, 271-277 (2001).
34. Moosmann P, Egli F, Stahel RA, Jost L. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 26, 568-572 (2003).
35. Haraf DJ, Rosen FR, Stenson K et al.: Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin. Cancer Res. 9, 5936-5943 (2003).
36. Constenla-Figueiras M, Mel-Lorenzo JR, Garcia-Arroyo FR et al.: A phase II study of weekly 1 hour paclitaxel (T) and 24-hour infusion with high-dose fluorouracil (5-FU) with leucovorin (LV) for advanced carcinoma of the head and neck. Ann. Oncol. 7(suppl 5), 80 (1996).
37. Fountzilas G, Stathopoulos G, Nicolaides C et al.: Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 10, 475-478 (1999).
38. Hitt R, Lopez-Pousa A, Rodriguez M et al.: Phase III study comparing cisplatin (P) and 5- fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head and neck cancer (LAHNC). Proc. Am. Soc. Clin. Oncol. 22, 496 [abstr 1997] (2003).
39. Hitt R, Jimeno A, Millan JM et al.: Phase II trial of dose-dense paclitaxel, cisplatin, 5- fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer 101, 768-775 (2004).
40. Papadimitrakopoulou VA, Ginsberg LE, Garden AS et al.: Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 98, 2214-2223 (2003).
41. Shin DM, Glisson BS, Khuri FR et al.: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 1325-1330 (1998).
42. Colevas AD, Busse PM, Norris CM et al.: Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J. Clin. Oncol. 16, 1331-1339 (1998).
43. Colevas A, Norris C, Tishler R et al.: Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 17, 3503-11 (1999).
44. Posner M, Glisson B, Frenette G, Al-Saraf M et al.: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 19, 1096-1104 (2001).
45. Janinis J, Papadakou M, Panagos G, et al.: Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am. J. Clin. Oncol. 24, 227-231 (2001).
46. Colevas AD, Norris CM, Tishler RB et al.: Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leuvorin (opTPFL) as induction for squamous cell carcinoma of the head and neck. (SCCHN). Am. J. Clin. Oncol. 25, 153-159 (2002).
47. Schrijvers D, Van Herpen C, Kerger J et al.: Docetaxel, cisplatin and 5- fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann. Oncol. 15, 638-645 (2004).
48. Tsukuda M, Mikami Y, Tanigaki Y et al.: Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int. J. Clin. Oncol. 9, 161-166 (2004).
49. Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 14, 801-7 (2003).
50. Vermorken JB, Remenar E, Van Herpen C et al.: Standard cisplatin/infusional 5- fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LASCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971). J. Clin. Oncol. 22(Suppl. 15), Abstract 5508 (2004).
51. Lovey J, Koronczay K, Remenar E et al.: Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother. Oncol. 68, 171-174 (2004).
52. Garden AS, Harris J, Vokes EE et al.: Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J. Clin. Oncol. 22, 2856-64 (2004).
53. Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin. Radiat. Oncol. 9(2 Suppl 1), 77-84 (1999).
54. Suntharalingam M, Haas ML, Conley BA et al.: The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1(49), 281-282 (2001).
55. Rosen FR, Haraf DJ, Kies MS et al.: Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin. Cancer Res. 9, 1689-97 (2003).
56. Fujii M, Tsukuda M, Satake B et al.: Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J. Clin. Oncol. 9, 107-112 (2004).
57. Calais G, Bardet E, Sire C et al.: Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 161-166 (2004).
58. Airoldi M, Cattel L, Cortesina G et al.: Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am. J. Clin. Oncol. 27, 155-163 (2004).
59. Baur M, Kienzer H, Schweiger J et al.: First-line therapy in head and neck cancer with docetaxel and cisplatin. Ann. Oncol. 9(Suppl. 4), 75 (Abstract 362) (1998).
60. Schffski P, Catimel G, Planting AS et al.: Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann. Oncol. 10, 119-122 (1999).
61. Mel J, Rodriguez R, Constenla M, Davila A, Fernadez-Piera M, Gonzales-Lama J. Phase II study of docetaxel and cisplatin as induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Preliminary results. Proc. Am. Soc. Clin. Oncol. 401a(Abstract 1549) (1999).
62. Caponigro F, Massa E, Manzione L et al.: Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann. Oncol. 12, 199-202 (2001).
63. Glisson B, Murphy B, Frenette G, Khuri F, Forastiere A. Phase II study of docetaxel and cisplatin combination in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 20, 1593-1599 (2002).
64. Baur M, Kienzer HR, Schweiger J et al.: Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 94, 2953-2958 (2002).
65. Gedlicka C, Formanek M, Selzer E, et al.: Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 63, 145-150 (2002).
66. Yabuuchi H, Kuroiwa T, Tajima T et al.: Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone. Clin. Oncol. 15, 467-472 (2003).
67. Ando M, Watanabe T, Sasaki Y et al.: A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br. J. Cancer 77, 1937-1943 (1998).
68. Fillipi M, Cupissol D, Calais G et al.: A phase II study of docetaxel and 5- fluorouracil in metastatic or recurrent squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 18, 402a (1999).
69. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR: A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann. Oncol. 11, 535-539 (2000).
70. Airoldi M, Cattel L, Marchionatti S et al.: Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am. J. Clin. Oncol. 26, 378-381 (2003).
71. EUCAN www-dep.iarc.fr/eucan/eucan.htm Accessed November 2005